Plandai’s Medical Marij. Research Could Advance From FDA Authorization of Clinical Trials Plandai Biotechnology (OTCQB: PLPL) timed its move into medical marij research perfectly. In Nov. the FDA approved clinical trials of the cannabis-based drug, Epidolex, and its impacts on epilepsy. This approval is a milestone decision by the FDA that puts the drug front and center and may show that the FDA is prepared to accept cannabis as a treatment. The FDA says this epilepsy therapy is 98 percent purified cannabidiol (CBD) made by GW Pharmaceuticals established out ofRead More